Jump to content
  • mission_statement.pngrrdiLogo384x64.jpg.3cd1bd79f5d066075bdd9

    Mission Statement

    The Rosacea Research & Development Institute [RRDi] is the first non-profit organization made by rosaceans for rosacea sufferers that will collect donations for rosacea research to be performed by physicians and biomedical research scientists and includes these specific goals:

    Goal # 1: To be the first non profit organization for rosacea patient advocacy and to find the cure for rosacea. 

    Goal # 2: To have a majority of rosaceans the right to vote who sits on the board of directors. This is in stark contrast to other rosacea non profit organizations comprised of non rosacea sufferers who are usually businessmen or dermatologists with a vested interest in treating rosacea. 

    Goal # 3: To make this the first rosacea specific non profit organization to utilize most of the donations for research and treatment development. This is in stark contrast to non profit organizations that spend 50% to 60% of their donations on paying their staff, board of directors, conventions for professional members or to pay private contractors for services.

    Goal # 4: To allow rosacea sufferers to guide where and how the money is spent on rosacea research and be the first non profit organization to allow rosaceans to be members of the corporation. Until June 7, 2004, the date of incorporation, there had been no other non profit organization that allowed input from rosacea sufferers.

    Goal # 5: To attain a level such that the RRDi can directly impact medical articles published on the subject, information disseminated to physicians and rosacea sufferers and apply positive pressure on the medical community.

    Goal #6: Continue to publish the Journal of the RRDi and fund all authors who contribute an article.

    Goal #7: To allow volunteer members to have a platform to voice their concerns about rosacea and to contribute information about rosacea. Our goal is 10K members. 

    For more information on how and why this non profit organization for rosacea was formed click here.

    Our Charter can be read by clicking here.

     



  • Member Statistics

    • Total Members
      1,669
    • Most Online
      499

    Newest Member
    Dallas
    Joined
  • image.png.9c7b476f653b05bf0b4220389b0df3

  • Posts

    • Expert Rev Clin Immunol. 2022 Sep 22. doi: 10.1080/1744666X.2022.2128334. Online ahead of print. ABSTRACT INTRODUCTION: : Recent advances in the understanding of the pathophysiology of rosacea have led to increased focus on the disease's immunologic etiology and to the development of immunologically based treatments. With many patients suffering from incomplete control, addressing the immune components of the disease process may provide a more effective treatment option for rosacea patients that may improve quality of life. AREAS COVERED: : This review will provide a brief overview of the pathophysiology or rosacea, as well as specific immunologic contributions to the disease state. Current standard-of-care treatments will be described, including anti-parasitic, anti-inflammatory agents, and antibiotics. Emphasis will be placed on treatments that target the immune components of the disease process. EXPERT OPINION: : Rosacea remains a difficult dermatologic disease to treat, partially due to an incomplete understanding of the disease pathophysiology. The immune pathophysiology of rosacea, particularly the key role of inflammation, has been clarified over the past decade. Identification of specific molecules, including cytokines and nuclear transcription factors, may allow for the development of targeted rosacea-specific biologic and topical treatments. However, medication nonadherence is a limiting factor to achieving symptomatic control among rosacea patients. Focusing on the development of oral or injectable forms of therapy may circumvent poor adherence. PMID:36137266 | DOI:10.1080/1744666X.2022.2128334 {url} = URL to article
×
×
  • Create New...

Important Information

Terms of Use